Lionel Terray

Terray Therapeutics Announces Multi-Target Collaboration with Bristol Myers Squibb

Retrieved on: 
Thursday, December 14, 2023
Bristol Myers Squibb, Therapy, NYSE, LOS, BMY, Drug discovery, Pharmaceutical industry, Lionel Terray

LOS ANGELES, Dec. 14, 2023 /PRNewswire/ -- Terray Therapeutics, a biotechnology company integrating scale experimentation and generative AI to improve the speed, cost, and success rate of small molecule drug discovery and development, today announced a multi-target collaboration agreement with Bristol Myers Squibb (NYSE: BMY) to discover and develop small molecule therapeutics in certain disease areas.

Key Points: 
  • LOS ANGELES, Dec. 14, 2023 /PRNewswire/ -- Terray Therapeutics, a biotechnology company integrating scale experimentation and generative AI to improve the speed, cost, and success rate of small molecule drug discovery and development, today announced a multi-target collaboration agreement with Bristol Myers Squibb (NYSE: BMY) to discover and develop small molecule therapeutics in certain disease areas.
  • Under the terms of the agreement, Terray will discover and develop small molecule compounds against a set of targets nominated by Bristol Myers Squibb using the Terray tNova platform, with Bristol Myers Squibb subsequently assuming responsibility for development and commercialization.
  • "We're proud to strategically partner with Bristol Myers Squibb," said Jacob Berlin, Ph.D., Chief Executive Officer, Terray Therapeutics.
  • "This agreement combines the scale, precision, and speed of our platform with the breadth and expertise of our collaborators at Bristol Myers Squibb to find new small molecule therapeutics."

Terray Therapeutics Announces Investment from NVIDIA to Enable Generative AI Design for Drug Discovery

Retrieved on: 
Thursday, November 9, 2023
Cloud, Alnylam Pharmaceuticals, Lionel Terray, LOS, Synthetic media, NVIDIA, AI, Therapy, Chemistry, Drug discovery, Medical device, Pharmaceutical industry, Video game

LOS ANGELES, Nov. 9, 2023 /PRNewswire/ -- Terray Therapeutics, a biotechnology company integrating scale experimentation and generative AI to improve the speed, cost, and success rate of small molecule drug discovery and development, today announced an equity investment by NVentures, NVIDIA's venture capital arm. Additional financing included a strong syndicate of new and existing institutional investors, including industry leaders John Maraganore, founding Chief Executive Officer of Alnylam Pharmaceuticals, and Bassil Dahiyat, founder and Chief Executive Officer of Xencor.

Key Points: 
  • "We're proud to work with NVIDIA," said Jacob Berlin, Ph.D., Chief Executive Officer of Terray Therapeutics.
  • These models enable our generative AI to efficiently explore a vast molecular space to solve complex problems in drug discovery."
  • Terray will leverage NVIDIA DGX™ Cloud to develop the world's most comprehensive chemistry foundation models for small molecules, some of which will be available on the NVIDIA BioNeMo™ cloud service for generative AI in drug discovery.
  • "Terray's novel approach to training AI foundation models on the NVIDIA accelerated computing platform will help Terray make important breakthroughs in drug discovery."

Terray Therapeutics Strengthens Leadership with Appointment of Sudha Parasuraman, MD to its Board of Directors

Retrieved on: 
Tuesday, May 16, 2023
Boston Children's Hospital, University, Dana–Farber Cancer Institute, Cone Health Women's Hospital, Biotechnology, University of Madras, St. Jude Children's Research Hospital, Sudha, Children's Hospital of Michigan, Child, Ribon, Harvard Medical School, Bortezomib, Ribociclib, Novartis, Inflammation, Hematology, Drug discovery, Hospital, Rare, Therapy, Independent Board for Presbyterian Foreign Missions, Management, Pharmaceutical industry, Lionel Terray, Brigham, MD

PASADENA, Calif., May 16, 2023 /PRNewswire/ -- Terray Therapeutics, a biotechnology company accelerating drug discovery through the application of computational approaches to precisely generated chemical data at scale, today announced the appointment of Sudha Parasuraman, MD, as an Independent Director.

Key Points: 
  • "We are tremendously excited to have Sudha join our Board of Directors," said Jacob Berlin, Ph.D., Chief Executive Officer of Terray.
  • "As Terray's internal and partnered programs move towards the clinic, we are fortunate to be able to draw on Sudha's deep clinical and strategic expertise."
  • "I am thrilled to join the Terray Board of Directors and work with the talented team of scientists they have assembled," said Dr. Parasuraman.
  • I look forward to bringing my strategic perspective on translational science, clinical development, and company-building to Terray."

Terray Therapeutics Appoints John Maraganore, Ph.D., as Strategic Advisor

Retrieved on: 
Tuesday, December 13, 2022
Biotechnology, Therapy, Senior advisor, Chicago (franchise), RNA interference, Norwest Venture Partners, Atlas Venture, Drug discovery, Automation, Patient, Science, Research, Biology, AI, Molecular biology, VC, Investment, Multimedia, Nanotechnology, University, Eye, Biochemistry, Partner, RNA, Management, Pharmaceutical industry, Alnylam Pharmaceuticals, Inclisiran, Lionel Terray

PASADENA, Calif., Dec. 13, 2022 /PRNewswire/ -- Terray Therapeutics, a biotechnology company accelerating drug discovery through the application of computational approaches to precisely generated chemical data at scale, today announced that John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, has been appointed as Strategic Advisor to the Board of Directors and Leadership Team.

Key Points: 
  • "We are thrilled to welcome John to the Terray team," said Jacob Berlin, Ph.D., Chief Executive Officer of Terray.
  • I welcome his experience and guidance to Terray as we continue bridging the gap between discovery and treatment."
  • "I am a firm believer in the power of insight-driven platforms to deliver sustainable innovation," said John Maraganore.
  • Terray Therapeutics is a biotechnology company operating at the convergence of AI, biology, medicinal chemistry, automation, and nanotechnology to propel drug discovery into the information age.

Terray Therapeutics Strengthens Leadership with Appointment of Bassil Dahiyat, Ph.D., as Board Independent Director

Retrieved on: 
Wednesday, November 30, 2022
Growth, Eid Dahiyat, American Chemical Society, Protein Society, Johns Hopkins University, AI, Mike Hopkins (basketball), Multimedia, Doctor of Philosophy, Therapy, Biotechnology, Patient, Bassil, Biomedical engineering, Cytokine, Protein engineering, Drug discovery, Protein, Nanotechnology, Automation, Biology, Biomedicine, Management, Pharmaceutical industry, Chemistry, California Institute of Technology, Lionel Terray

PASADENA, Calif., Nov. 30, 2022 /PRNewswire/ -- Terray Therapeutics, a biotechnology company accelerating drug discovery through the application of computational approaches to precisely generated chemical data at scale, today announced the appointment of Bassil Dahiyat, Ph.D., as an Independent Director.

Key Points: 
  • "We are incredibly fortunate to have Bassil join the Terray team," said Jacob Berlin, Ph.D., Chief Executive Officer of Terray.
  • His deep experience in both the field and in company building will be invaluable to Terray during this period of growth."
  • Dr. Dahiyat also serves as a member of the board of directors of Kodiak Sciences, a publicly traded biopharmaceutical company.
  • "I am thrilled to join the Terray Board of Directors and work with the talented team of scientists they have assembled," said Dr. Dahiyat.

Terray Therapeutics and Calico Enter into a Multi-Target Collaboration to Discover Small Molecule Therapeutics for Age-Related Diseases

Retrieved on: 
Wednesday, October 12, 2022
Therapy, Machine learning, Patient, Biotechnology, Biology, Research, Multimedia, Alphabet, Cancer, Automation, Drug discovery, AI, Degenerative disease, Calico (company), Nanotechnology, Ageing, Pharmaceutical industry, Textile printing, Calico, Lionel Terray, Chemical substance

PASADENA, Calif. and SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 /PRNewswire/ -- Terray Therapeutics, a biotechnology company accelerating drug discovery through the application of computational approaches to precisely generated chemical data at scale; and Calico Life Sciences, a biotechnology organization focused on age-related interventions and founded by Alphabet and Arthur D. Levinson, today announced a research collaboration to discover and develop small molecule therapeutics for diseases of aging, including cancer. 

Key Points: 
  • Under the terms of the agreement, Terray and Calico will identify small molecule leads against a set of targets nominated by Calico using the Terray tNova platform, with Calico subsequently assuming responsibility for development and commercialization.
  • Terray will receive an upfront payment and is eligible to receive milestones as well as tiered royalties on net sales.
  • "Our combined expertise will leverage the scale, precision, and speed of our tNova platform to rapidly discover and advance therapeutics for patients."
  • "We look forward to partnering with the team at Terray to jointly discover first-in-class therapeutics against age-related diseases."

Terray Therapeutics Expands Scientific Advisory Board to Advance AI-Driven Small Molecule Drug Discovery

Retrieved on: 
Tuesday, July 12, 2022
Bachelor of Science in Human Biology, Biotechnology, Leadership, Loughborough University, Multimedia, Science, Engineering, Therapy, Coronavirus Scientific Advisory Board (Turkey), University, Patient, Drug discovery, Medicinal chemistry, Doctor of Philosophy, Lionel Terray, Automation, Nanotechnology, Growth, Biology, Pharmaceutical industry, Medical device, Biophysics, AI

PASADENA, Calif., July 12, 2022 /PRNewswire/ -- Terray Therapeutics, a biotechnology company propelling drug discovery into the information age, today announced the appointment of Fiona Black, PhD to its Scientific Advisory Board, adding valuable expertise in interdisciplinary technology development of both market-leading, end-to-end product solutions and operationally efficient and scalable manufacturing processes.

Key Points: 
  • "We are thrilled to welcome Dr. Black to our Scientific Advisory Board," said Chief Executive Officer Jacob Berlin, PhD.
  • "The ability to measure precise chemical-biological interaction data at scale addresses a longstanding pain point in drug discovery.
  • I am delighted to join the Scientific Advisory Board at this pivotal stage for the company."
  • Terray Therapeutics is an emerging biotechnology company led by pioneers and long-time leaders in AI, medicinal chemistry, biology and preclinical development, automation, and nanotechnology to propel drug discovery into the information age.

Terray Therapeutics Expands Leadership Team with Fez Ujjainwalla, PhD as Head of Business and Adam D. Hughes, PhD as Head of Chemistry

Retrieved on: 
Tuesday, March 1, 2022
Data science, Computation, Head, Degenerative disease, Automation, Hughes, Therapy, Medicine, MC4R, Multimedia, Machine learning, Chemistry (relationship), Biotechnology, Obesity, DRS, Business development, Mechanics, COPD, Drug discovery, Patient, Nanotechnology, Research, CEO, Doctor of Philosophy, Computational chemistry, Medicinal chemistry, Pharmaceutical industry, Management, Medical device, Lionel Terray, Amgen, Business, Biology, AI, Merck

PASADENA, Calif., March 1, 2022 /PRNewswire/ -- Terray Therapeutics, a biotechnology company propelling drug discovery into the information age, today announced the appointments of Feroze (Fez) Ujjainwalla, PhD, as Head of Business, and Adam D. Hughes, PhD, as Head of Chemistry.

Key Points: 
  • PASADENA, Calif., March 1, 2022 /PRNewswire/ -- Terray Therapeutics, a biotechnology company propelling drug discovery into the information age, today announced the appointments of Feroze (Fez) Ujjainwalla, PhD, as Head of Business, and Adam D. Hughes, PhD, as Head of Chemistry.
  • "We are thrilled to welcome Fez and Adam to the team as we start this new chapter in the Terray story," said Chief Executive Officer Jacob Berlin, PhD.
  • "They each bring over 20 years of drug discovery and development experience to our interdisciplinary team of highly skilled computational scientists, biologists, chemists and engineers.
  • "I'm very excited to join the Terray team at this momentous stage," said Dr. Ujjainwalla.